Screener
Regeneron Pharmaceuticals REGN Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Intangible assets, net | 1,309.8 | 1,257.4 |
| Deferred tax assets | 4,381.4 | 4,077.2 |
| Other noncurrent assets | 2,306.2 | 1,821.2 |
| Total assets | $41,730.6 | $40,558.7 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,159.3 | $939.0 |
| Accrued expenses and other current liabilities | 2,966.5 | 2,876.4 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's total assets?
- Regeneron Pharmaceuticals (REGN) reported total assets of $41.73B in Q2 2026.
- How has Regeneron Pharmaceuticals's total assets changed year-over-year?
- Regeneron Pharmaceuticals's total assets increased by 9.2% year-over-year, from $38.22B to $41.73B.
- What is the long-term trend for Regeneron Pharmaceuticals's total assets?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total assets has grown at a 18.8% compound annual growth rate (CAGR), from $17.16B to $40.56B.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Regeneron Pharmaceuticals's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude